EMA Authorised: Stivarga (regorafenib) — Bayer Pharma AG

View source ↗

Summary

The EMA authorised Stivarga (regorafenib) for colorectal cancer (colorectal neoplasms). The decision was issued on 26 February 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Stivarga (regorafenib)

Snippet

Status: Authorised. Therapeutic area: Colorectal Neoplasms. MAH: Bayer Pharma AG. Decision date: 26/02/2026